Genomics, nanotech get bigger share of EU budget
This article was originally published in Clinica
Executive Summary
Genomics, biotechnology and nanotechnology are among the priority areas of the European Union's R&D budget for 2002-2006. Genomics and biotechnology are to receive Euro2 billion ($1.82 billion) of the Euro16.27 billion available, with nanotechnologies and emerging technologies receiving a share of over Euro3.5 billion.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.